The frequency of thrombotic events among adults given antifibrinolytic drugs for spontaneous bleeding: Systematic review and meta-analysis of observational studies and randomized trials

Current Drug Safety

Volumn 7, Issue 1, 2012, Pages 44-54

  Ross, Jenny ^a   Salman, Rustam Al Shahi ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cerebral infarction; Deep vein thrombosis; Intracerebral haemorrhage; Myocardial infarction; Pulmonary embolism; Tranexamic acid

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; APROTININ; TRANEXAMIC ACID;

BLEEDING; BRAIN HEMORRHAGE; BRAIN INFARCTION; COMORBIDITY; DEEP VEIN THROMBOSIS; DRUG CONTRAINDICATION; DRUG SAFETY; EPISTAXIS; HEART INFARCTION; HUMAN; LIMB ISCHEMIA; LUNG EMBOLISM; MENORRHAGIA; META ANALYSIS; OBSERVATIONAL STUDY; POSTPARTUM HEMORRHAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; STUDY DESIGN; SUBARACHNOID HEMORRHAGE; SYSTEMATIC REVIEW; THROMBOSIS; TREATMENT DURATION; TREATMENT INDICATION; ULCERATIVE COLITIS; UPPER GASTROINTESTINAL BLEEDING; URINARY TRACT HEMORRHAGE; ADULT; AGED; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; MIDDLE AGED; PATHOLOGY; STATISTICAL MODEL;

6-AMINOCAPROIC ACID; ADULT; AGED; ANTIFIBRINOLYTIC AGENTS; APROTININ; HEMORRHAGE; HUMANS; MIDDLE AGED; MODELS, STATISTICAL; SUBARACHNOID HEMORRHAGE; THROMBOSIS; TRANEXAMIC ACID;

EID: 84867651181     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488612800492744     Document Type: Review

References (105)

1. Roberts I, Shakur H, Ker K, Coats T, on behalf of the CRASH-2 Trial collaborators. Antifibrinolytic drugs for acute traumatic injury. Cochrane Database Syst Rev 2011; 1: CD004896.
2. Henry DA, Carless PA, Moxey AJ, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2011; 1: CD001886.
3. Lethaby A, Farquhar C, Cooke I. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev 2000; 4: CD000249.
4. Gluud LL, Klingenberg SL, Langholz E. Tranexamic acid for upper gastrointestinal bleeding. Cochrane Database Syst Rev 2012; 1: CD006640.
5. Roos YB, Rinkel GJE, Vermeulen M, Algra A, van Gijn J. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2003; 2: CD001245.
6. van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol 2010; 9: 167-76.
7. Josephson CB, Frantzias J, Samarasekera N, Al-Shahi Salman R. The persisting burden of intracerebral haemorrhage: can effective treatments be found? PLoS Med 2010; 7: e1000353.
8. Al-Shahi Salman R. Haemostatic drug therapies for acute spontaneous intracerebral haemorrhage. Cochrane Database Syst Rev 2009; 4: CD005951.
9. Diringer MN, Skolnick BE, Mayer SA, Steiner T, Davis SM, Brun NC. Risk of thromboembolic events in controlled trials of rFVIIa in spontaneous intracerebral hemorrhage. Stroke 2008; 39: 850-6.
10. Diringer MN, Skolnick BE, Mayer SA, Steiner T, Davis SM, Brun NC. Thromboembolic events with recombinant factor VII in spontaneous intracerebral hemorrhage. Results from the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial. Stroke 2010; 41: 48-53.
11. Sugg RM, Gonzales NR, Matherne DE, et al. Myocardial injury in patients with intracerebral hemorrhage treated with recombinant factor VIIa. Neurology 2006; 67(6):1053-5.
12. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010; 363(19):1791-800.
13. Sorimachi T, Fujii Y, Morita K, Tanaka R. Rapid administration of antifibrinolytics and strict blood pressure control for intracerebral hemorrhage. Neurosurgery 2005; 57: 837-43.
14. Ojacastro MF, Tabuena MP, Dulos ID, Tabuena RP. Efficacy of tranexamic acid in reducing hematoma volume in patients with hypertensive intracerebral hemorrhage. Int J Stroke 2008; 3: 197-8 (Abstract).
15. Adams HP, Nibbelink DW, Torner JC, Sahs AL. Antifibrinolytic therapy in patients with aneurysmal subarachnoid hemorrhage: A report of the Cooperative Aneurysm Study. Arch Neurol 1981; 38: 25-9.
16. Andersch B, Milsom I, Rybo G. An objective evaluation of flurbiprofen and tranexamic acid in the treatment of idiopathic menorrhagia. Acta Obstet Gynecol Scand 1988; 67: 645-8.
17. Andersson L, Nilsson IM. AMCA (aminomethyl cyclohexane carboxylic acid, Cyklo-kapron) a potent haemostatic agent in urinary tract bleeding. Scand J Urol Nephrol 1969; 3: 169-76.
18. Avvisati G, ten Cate JW, Buller HR, Mandelli F. Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet 1989; 2: 122-4.
19. Beck DW, Adams HP, Flamm ES, Godersky JC, Loftus CM. Combination of aminocaproic acid and nicardipine in treatment of aneurysmal subarachnoid hemorrhage. Stroke 1988; 19: 63-7.
20. Ben-Bassat I, Douer D, Ramot B. Tranexamic acid therapy in acute myeloid leukemia: possible reduction of platelet transfusions. Eur J Haematol 1990; 45: 86-9.
21. Biggs JC, Hugh TB, Dodds AJ. Tranexamic acid and upper gastrointestinal haemorrhage -- a double-blind trial. Gut 1976; 17: 729-34.
22. Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: randomized controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. Br Med J 1996; 313: 579-82.
23. Callender ST, Warner GT, Cope E. Treatment of menorrhagia with tranexamic acid. A double-blind trial. Br Med J 1970; 4: 214-6.
24. Chandra B. Treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm with tranexamic acid: a double-blind clinical trial. Ann Neurol 1978; 3: 502-4.
25. Chowdhary UM, Carey PC, Hussein MM. Prevention of early recurrence of spontaneous subarachnoid haemorrhage by epsilonaminocaproic acid. Lancet 1979; 1: 741-3.
26. Chowdhary UM, Sayed K. Comparative clinical trial of epsilon amino-caproic acid and tranexamic acid in the prevention of early recurrence of subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 1981; 44: 810-3.
27. Cormack F, Chakrabarti RR, Jouhar AJ, Fearnley GR. Tranexamic acid in upper gastrointestinal haemorrhage. Lancet 1973; 1: 1207-8.
28. Engqvist A, Brostrom O, von Feilitzen F, et al. Tranexamic acid in massive haemorrhage from the upper gastrointestinal tract: a double-blind study. Scand J Gastroenterol 1979; 14: 839-44.
29. Fodstad H, Forssell A, Liliequist B, Schannong M. Antifibrinolysis with tranexamic acid in aneurysmal subarachnoid hemorrhage: a consecutive controlled clinical trial. Neurosurgery 1981; 8: 158-65.
30. Fodstad H, Liliequist B, Schannong M, Thulin CA. Tranexamic acid in the preoperative management of ruptured intracranial aneurysms. Surg Neurol 1978; 10: 9-15.
31. Gelmers HJ. Prevention of recurrence of spontaneous subarachnoid haemorrhage by tranexamic acid. Acta Neurochir 1980; 52: 45-50.
32. Geronemus R, Herz DA, Shulman K. Streptokinase clot lysis time in patients with ruptured intracranial aneurysms. J Neurosurg 1974; 40: 499-503.
33. Gibbs JR, Corkill AG. Use of an anti-fibrinolytic agent (tranexamic acid) in the management of ruptured intracranial aneurysms. Postgrad Med J 1971; 47: 199-200.
34. Girvin JP. The use of antifibrinolytic agents in the preoperative treatment of ruptured intracranial aneurysms. Trans Am Neurol Assoc 1973; 98: 150-2.
35. Guidetti B, Spallone A. The role of antifibrinolytic therapy in the preoperative management of recently ruptured intracranial aneurysms. Surg Neurol 1981; 15: 239-48.
36. Gultekin M, Diribas K, Buru E, Gokceoglu MA. Role of a nonhormonal oral anti-fibrinolytic hemostatic agent (tranexamic acid) for management of patients with dysfunctional uterine bleeding. Clin Exp Obstet Gynecol 2009; 36: 163-5.
37. Gunawan B, Runyon B. The efficacy and safety of epsilonaminocaproic acid treatment in patients with cirrhosis and hyperfibrinolysis. Aliment Pharmacol Ther 2006; 23: 115-20.
38. Hillman J, Fridriksson S, Nilsson O, Yu Z, Saveland H, Jakobsson K. Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: A prospective randomized study. J Neurosurg 2002; 97: 771-8.
39. Hollanders D, Thomson JM, Schofield PF. Tranexamic acid therapy in ulcerative colitis. Postgrad Med J 1982; 58: 87-91.
40. Kalmadi S, Tiu R, Lowe C, Jin T, Kalaycio M. Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. Cancer 2006; 107: 136-40.
41. Kaste M, Ramsay M. Tranexamic acid in subarachnoid hemorrhage. A double-blind study. Stroke 1979; 10: 519-22.
42. Kriplani A, Kulshrestha V, Agarwal N, Diwakar S. Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. J Obstet Gynaecol 2006; 26: 673-8.
43. Maurice-Williams RS. Prolonged antifibrinolysis: an effective nonsurgical treatment for ruptured intracranial aneurysms? Br Med J 1978; 1: 945-7.
44. Mehta BC, Parekh DS. Epsilon-amino-caproic acid in the treatment of menorrhagia. J Postgrad Med 1977; 23: 121-3.
45. Milsom I, Andersson K, Andersch B, Rybo G. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynaecol 1991; 164: 879-83.
46. Mowat NAG, Douglas AS, Brunt PW, McIntosh JAR, King PC, Boddy K. Epsilon-aminocaproic acid therapy in ulcerative colitis. Digest Dis Sci 1973; 18: 959-65.
47. Mullan S, Hanlon K, Brown F. Management of 136 consecutive supratentorial berry aneurysms. J Neurosurg 1978; 49: 794-804.
48. Nilsson L, Rybo G. Treatment of menorrhagia with an antifibrinolytic agent, tranexamic acid (AMCA). A double-blind investigation. Acta Obstet Gynecol Scand 1967; 46: 572-80.
49. Nilsson L, Rybo G. Treatment of menorrhagia with epsilonaminocaproic acid. Acta Obstet Gynecol Scand 1965; 44: 467-73.
50. Pinna G, Pasqualin A, Vivenza C, Da Pian R. Rebleeding, ischaemia and hydrocephalus following anti-fibrinolytic treatment for ruptured cerebral aneurysms: a retrospective clinical study. Acta Neurochir 1988; 93: 77-87.
51. Piriyawat P, Morgenstern LB, Yawn DH, Hall CE, Grotta JC. Treatment of acute intracerebral hemorrhage with epsilonaminocaproic acid: a pilot study. Neurocrit Care 2004; 1: 47-51.
52. Post KD, Flamm ES, Goodgold A, Ransohoff J. Ruptured intracranial aneurysms. Case morbidity and mortality. J Neurosurg 1977; 46: 290-5.
53. Preston JT, Cameron IT, Adams EJ, Smith SK. Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. Br J Obstet Gynaecol 1995; 102: 401-6.
54. Roos Y. Antifibrinolytic treatment in subarachnoid hemorrhage: a randomized placebo-controlled trial. STAR Study Group. Neurology 2000; 54: 77-82.
55. Schisano G. The use of antifibrinolytic drugs in aneurysmal subarachnoid hemorrhage. Surg Neurol 1978; 10: 217-22.
56. Sengupta RP, So SC, Villarejo-Ortega F. Use of epsilon aminocaproic acid (EACA) in the preoperative management of ruptured intracranial aneurysms. J Neurosurg 1976; 44: 479-84.
57. Shpilberg O, Blumenthal R, Sofer O, et al. A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. Leuk Lymphoma 1995; 19: 141-4.
58. Shucart WA, Hussain SK, Cooper PR. Epsilon-aminocaproic acid and recurrent subarachnoid hemorrhage: a clinical trial. J Neurosurg 1980; 53: 28-31.
59. Srinil S, Jaisamrarn U. Treatment of idiopathic menorrhagia with tranexamic acid. J Med Assoc Thai 2005; 88: S1-6.
60. Starke RM, Kim GH, Fernandez A, et al. Impact of a protocol for acute antifibrinolytic therapy on aneurysm rebleeding after subarachnoid hemorrhage. Stroke 2008; 39: 2617-21.
61. Stroobandt G, Lambert O, Menard E. The association of tranexamic acid and nimodipine in the pre-operative treatment of ruptured intracranial aneurysms. Acta Neurochir 1998; 140: 148-60.
62. Svanberg L, Astedt B, Nilsson IM. Abruptio placentae--treatment with the fibrinolytic inhibitor tranexamic acid. Acta Obstet Gynecol Scand 1980; 59: 127-30.
63. Tsementzis SA, Hitchcock ER, Meyer CH. Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study. Acta Neurochir 1990; 102: 1-10.
64. Uttley D, Richardson AE. E-aminocaproic acid and subarachnoid haemorrhage. Lancet 1974; 304: 1080-1.
65. van Rossum J, Wintzen AR, Endtz LJ, Schoen JH, de Jonge H. Effect of tranexamic acid on rebleeding after subarachnoid hemorrhage: a double-blind controlled clinical trial. Ann Neurol 1977; 2: 238-42.
66. Vermeulen M, Lindsay KW, Murray GD, et al. Antifibrinolytic treatment in subarachnoid hemorrhage. N Engl J Med 1984; 311: 432-7.
67. Vermylen J, Verhaegen-Declercq M, Verstraete M, Fierens F. A double-blind study of the effect of tranexamic acid in essential menorrhagia. Thromb Diath Haemorrh 1968; 20: 583-7.
68. von Holstein CC, Eriksson SB, Kallen R. Tranexamic acid as an aid to reducing blood transfusion requirements in gastric and duodenal bleeding. Br Med J (Clin Res Ed) 1987; 294: 7-10.
69. White A, O'Reilly BF. Oral tranexamic acid in the management of epistaxis. Clin Otolaryngol 1988; 13: 11-6.
70. Yang H, Zheng S, Shi C. Clinical study on the efficacy of tranexamic acid in reducing postpartum blood loss: a randomized, comparative, multicenter trial. Zhonghua Fu Chan Ke Za Zhi 2001; 36: 590-2.
71. Adams HP Jr, Kassell NF, Torner JC, Haley EC Jr. Predicting cerebral ischemia after aneurysmal subarachnoid hemorrhage: influences of clinical condition, CT results, and antifibrinolytic therapy. A report of the Cooperative Aneurysm Study. Neurology 1987; 37: 1586-91.
72. Ameen AA, Illingworth R. Anti-fibrinolytic treatment in the preoperative management of subarachnoid haemorrhage caused by ruptured intracranial aneurysm. J Neurol Neurosurg Psychiatry 1981; 44: 220-6.
73. Barer D, Ogilvie A, Henry D, et al. Cimetidine and tranexamic acid in the treatment of acute upper-gastrointestinal-tract bleeding. N Engl J Med 1983; 308: 1571-5.
74. Brown JE, Olujohungbe A, Chang J, et al. All-trans retinoic acid (ATRA) and tranexamic acid: A potentially fatal combination in acute promyelocytic leukaemia. Br J Haematol 2000; 110: 1010-2.
75. Cameron M. Proceedings of the Society of British Neurological Surgeons: A meeting of the Society of British Neurological Surgeions was held in Plymouth on 5-6 April 1979. J Neurol Neurosurg Psychiatry 1979; 42: 962-8.
76. Cronstedt J, Östberg H, Carling L, et al. Diagnosis and Treatment of Acute Gastrointestinal Haemorrhage in a Small District Hospital. Acta Med Scand 1976; 199: 129-32.
77. Edlund M, Andersson K, Rybo G, Lindoff C, Astedt B, von Schoultz B. Reduction of menstrual blood loss in women suffering from idiopathic menorrhagia with a novel antifibrinolytic drug (Kabi 2161). Br J Obstet Gynaecol 1995; 102: 913-7.
78. Gibbs JR, O'Gorman P. Fibrinolysis in subarachnoid haemorrhage. Postgrad Med J 1967; 43: 779-84.
79. Hawkey GM, Cole AT, McIntyre AS, Long RG, Hawkey CJ. Drug treatments in upper gastrointestinal bleeding: value of endoscopic findings as surrogate end points. Gut 2001; 49: 372-9.
80. Kassell NF, Torner JC, Adams HP Jr. Antifibrinolytic therapy in the acute period following aneurysmal subarachnoid hemorrhage. Preliminary observations from the Cooperative Aneurysm Study. J Neurosurg 1984; 61: 225-30.
81. Knuckey NW, Stokes BA. Medical management of patients following a ruptured cerebral aneurysm, with epsilon-aminocaproic acid, kanamycin, and reserpine. Surg Neurol 1982; 17: 181-5.
82. Kouides PA, Byams VR, Philipp CS, et al. Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. Br J Haematol 2009; 145: 212-20.
83. Leipzig TJ, Redelman K, Horner TG. Reducing the risk of rebleeding before early aneurysm surgery: a possible role for antifibrinolytic therapy. J Neurosurg 1997; 86: 220-5.
84. Mullan S, Dawley J. Antifibrinolytic Therapy for Intracranial Aneurysms. J Neurosurg 1968; 28: 21-3.
85. Mullan S. Conservative management of the recently ruptured aneurysm. Surg Neurol 1975; 3: 27-32.
86. Nibbelink DW, Torner JC, Henderson WG. Intracranial aneurysms and subarachnoid hemorrhage. A cooperative study. Antifibrinolytic therapy in recent onset subarachnoid hemorrhage. Stroke 1975; 6: 622-9.
87. Ostberg HO, Ulfberg J, Wennerholm M, Zellner K. Acute gastrointestinal haemorrhage. Experience with early panendoscopy and tranexamic acid in a rural hospital. Acta Chir Scand 1977; 143: 463-8.
88. Ransohoff J, Goodgold A, Benjamin MV. Preoperative management of patients with ruptured intracranial aneurysms. J Neurosurg 1972; 36: 525-30.
89. Rosenorn J, Eskesen V, Espersen JO, Haase J, Schmidt K. Antifibrinolytic therapy in patients with aneurysmal subarachnoid haemorrhage. Br J Neurosurg 1988; 2: 447-53.
90. Sabovic M, Lavre J, Vujkovac B. Tranexamic acid is beneficial as adjunctive therapy in treating major upper gastrointestinal bleeding in dialysis patients. Nephrol Dial Transplant 2003; 18: 1388-91.
91. Spallone A. Antifibrinolytics in aneurysmal subarachnoid haemorrhage. A retrospective comparison of two different forms of antifibrinolytic therapy. Acta Neurochir 1982; 63: 245-50.
92. Wassenaar T, Black J, Kahl B, et al. Acute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients. Hematol Oncol 2008; 26: 241-6.
93. Bergqvist D, Dahlgren S, Hessman Y. Local inhibition of the fibrinolytic system in patients with massive upper gastrointestinal hemorrhage. Ups J Med Sci 1980; 85: 173-8.
94. Andersson L. Antifibrinolytic drugs in the treatment of urinary tract haemorrhage. Prog Surg 1972; 10: 76-93.
95. Corkill G. Earlier operation and antifibrinolytic therapy in the management of aneurysmal subarachnoid haemorrhage. Med J Aust 1974; 1: 468-70.
96. Fricke W, Alling D, Kimball J, Griffith P, Klein H. Lack of efficacy of tranexamic acid in thrombocytopenic bleeding. Transfusion 1991; 31: 345-8.
97. Gallardo RL, Gardner FH. Aminocaproic acid for bleeding in thrombocytopenic patients. Tex Med 1985; 81: 30-2.
98. Profeta G, Castellano F, Guarnieri L, Cigliano A, Amborsio A. Antifibrinolytic therapy in the treatment of subarachnoid haemorrhage caused by arterial aneurysms. J Neurosurg Sci 1975; 19: 77-8.
99. Sato S, Ishibashi Y, Endo T, Watanabe T, Nakajima K. Clinical use of E-amino-N-caproic acid on metropathia haemorrhagica. Keio J Med 1959; 8: 267-78.
100. Spallone A, Pastore FS, Rizzo A, Guidetti B. Low-dose tranexamic acid combined with aprotinin in the pre-operative management of ruptured intracranial aneurysms. Neurochirurgia 1987; 30: 172-6.
101. Tovi D. The use of antifibrinolytic drugs to prevent early recurrent aneurysmal subarachnoid haemorrhage. Acta Neurol Scand 1973; 49: 163-75.
102. Tscheikuna J, Chvaychoo B, Naruman C, Maranetra N. Tranexamic acid in patients with hemoptysis. J Med Assoc Thai 2002; 85: 399-404.
103. Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, Williamson PR. The impact of outcome reporting bias in randomized controlled trials on a cohort of systematic reviews. Br Med J 2010; 340: 365.
104. Ngaage DL, Bland JM. Lessons from aprotinin: is the routine use and inconsistent dosing of tranexamic acid prudent? Meta-analysis of randomized and large matched observational studies. Eur J Cardiothorac Surg 2010; 37: 1375-83.
105. Andersen KK, Olsen TS, Dehlendorff C, Kammersgaard LP. Hemorrhagic and ischaemic strokes compared. Stroke 2009; 40: 2068-72.